Evidence map›Paper›PMID 42613797›Full record

ArticleCNS neuroscience & therapeutics2026

VMAT-DAT-Dopamine Regulatory System Involved in the Protective Effect of 3-n-Butylphthalide Against Ischemic Stroke.

Xiao-Ting Zhou, Qin Liu, Ming Chen, Ruo-Xi Zhang, Yi-Ling Su, Ding-Feng Su, Ai-Jun Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiao-Ting ZhouDepartment of Pharmacy Research, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Qin LiuDepartment of Pharmacy Research, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ming ChenMOE Frontier Center for Brain Science, Institutes of Brain Science, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China.
Ruo-Xi ZhangDepartment of Pharmacy Research, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yi-Ling SuNingbo New Drug Evaluation Center, Ningbo, China.
Ding-Feng SuNingbo New Drug Evaluation Center, Ningbo, China.
Ai-Jun LiuDepartment of Pharmacy Research, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID https://orcid.org/0000-0003-3256-644X

Funding

National Key Research and Development Program of China 2019YFC1708504National Natural Science Foundation of China 82273984Three Year Action Plan for Shanghai to Further Accelerate the Inheritance, Innovation and Development of Traditional Chinese Medicine (2025- 2027) 1-1-2
6 · The paper itself

Abstract

aimsA stable uptake-release cycle system of dopamine is dependent upon two transporters, dopamine transporter (DAT) and vesicular monoamine transporter (VMAT). Whether the regulation system of dopamine is involved in the neuroprotection mediated by 3-n-butylphthalide (NBP) against ischemic stroke injury is unclear.

methodsMiddle cerebral artery occlusion (MCAO) was subjected to evaluate the protection of NBP. In vivo microdialysis measurements of neurotransmitters were recorded in the ischemic penumbral area. Brain slices were prepared in MCAO mice to record synaptic function, including miniature excitatory postsynaptic currents (mEPSCs) and miniature inhibitory postsynaptic currents (mIPSCs).

resultsNBP decreased the infarct size with a dose-dependent manner, and significantly reduced the level of glutamate, while markedly increasing dopamine release. The expressions of DAT and VMAT were significantly decreased by MCAO, which were reversely enhanced by NBP. Pretreatment with VMAT inhibitor, reserpine, abolished the dopamine increase and eliminated the neuroprotection of NBP. The balance between excitatory and inhibitory synaptic transmission is disturbed by ischemic injury and reversed by NBP. Reserpine eliminated the effect of NBP against the disturbance of mEPSCs and mIPSCs. Inhibition of dopamine-1 receptor (D

conclusionThe neuroprotective effect of NBP against cerebral ischemic injury may involve the upregulation of the VMAT-DAT-dopamine cycle, which appears to contribute to the amelioration of synaptic dysfunction. The activation of D

Indexed as

BenzofuransDopamineDopamine Plasma Membrane Transport ProteinsIschemic StrokeNeuroprotective AgentsVesicular Monoamine Transport ProteinsAnimalsDisease Models, AnimalDose-Response Relationship, DrugExcitatory Postsynaptic PotentialsInfarction, Middle Cerebral ArteryMaleMiceMice, Inbred C57BL3-n-butylphthalideBenzofuransDopamineDopamine Plasma Membrane Transport ProteinsNeuroprotective AgentsSlc18a2 protein, mouseVesicular Monoamine Transport Proteins3‐n‐butylphthalide (NBP)adenosine A1 receptors (A1Rs)D1 receptor (D1R)dopaminedopamine transporter (DAT)ischemic strokevesicular monoamine transporter (VMAT)

Identifiers

PMID42613797
PMCPMC13486960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.